Physician profile
Jordan Morrison
NPI 1912773854
$1,498.66
in general payments reported to CMS, 2019-2025
21 companies · $525 in 2025
The $525 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $869 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $240.99 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $213.08 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $207.37 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Otsuka America Pharmaceutical, INC. | $156.92 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $92.02 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $55.37 | 2024-2025 | Fanapt |
| Averitas Pharma INC. | $50.74 | 2023-2024 | Qutenza |
| Abbvie INC. | $48.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.26 | 2024-2025 | Ofev |
| Amgen INC. | $43.84 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $39.51 | 2024-2025 | Austedo Xr, Austedo Xr |
| Indivior INC. | $38.92 | 2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.42 | 2025 | Xifaxan |
| Lundbeck LLC | $34.74 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $34.52 | 2024 | Capvaxive |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.14 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $28.92 | 2024 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $28.24 | 2024 | |
| Shield Therapeutics INC | $27.36 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $25.58 | 2023 | Gemtesa |
| Neurelis, INC. | $17.40 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.